SCHEMBL5580038

SCHEMBL5580038

Cc1ccc(C2CNCc3ccc(Cl)cc3O2)nc1

nearest known ligand 0.40

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 1/20 0.32
PNMT P11086 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3707388 0.79
SCHEMBL5533233 0.78 SLC6A2 (0.39) NISCH
SCHEMBL17468757 0.66 MAOB (0.44)
SCHEMBL17459292 0.65 ESR1 (0.40) PNMT
SCHEMBL31116796 0.65
SCHEMBL20198840 0.64 CCR1 (0.50)
SCHEMBL3700062 0.64 CCR1 (0.30)
SCHEMBL20297273 0.62 ALDH1A1 (0.36) PNMT
SCHEMBL18325492 0.62 ALDH1A1 (0.36) PNMT
SCHEMBL17459280 0.62 GUSB (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122843-A1 Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases ASTRAZENECA AB (SE) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122843-A1 Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases APP, BACE1, PSEN1 NISCH 1506/4885PNMT 468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.